Shots:
- Inocras is advancing the clinical adoption of whole-genome sequencing (WGS) by transforming it from a research tool into a standardized diagnostic workflow, refining its algorithms through thousands of real-world patient cases to deliver actionable genomic insights in routine care.
- Through platforms such as CancerVision, RareVision, and MRDVision, the company integrates deep genomic analytics, AI-driven bioinformatics, and clinical services like genetic counseling and trial matching to support precision oncology and rare disease decision-making.
- PharmaShots welcomes Jehee Suh of Inocras for an engaging dialogue on scaling whole-genome sequencing globally, leveraging AI-driven genome intelligence, and shaping the future of precision medicine and clinical research.
Saurabh: Welcome to PharmaShots Viewpoints! Inocras is advancing whole-genome sequencing for real-world care. What was the defining moment that shaped its journey from concept to a clinically actionable platform?
Jehee: The defining moment was when we demonstrated, through real-world clinical use, that whole-genome sequencing could move beyond research and become an everyday diagnostic tool. We focused on making WGS practical and clinically actionable by continuously refining our algorithms using thousands of real patient cases. A second pivotal step was moving our headquarters from South Korea to San Diego, enabling us to build deeper relationships with leading hospitals, research centers, and global technology partners at the epicenter of the genomics ecosystem.
Saurabh: Whole-genome sequencing has long promised transformation but faced adoption hurdles. How is Inocras addressing cost, complexity, and clinical integration challenges?
Jehee: WGS adoption has historically been held back by complexity and cost. Our approach has been to operationalize whole-genome sequencing into a standardized clinical workflow that aligns with real clinical timelines and decision-making. We’ve evolved from a research-oriented bioinformatics technology company into a clinical diagnostics provider delivering accurate, standardized, and cost-effective whole-genome solutions for routine care. That’s only possible because we keep improving performance and utility through continuous learning from large volumes of real cases.
Saurabh: With CancerVision, RareVision, and MRDVision, Inocras spans oncology and rare diseases. How does the company balance deep genomic analytics with practical clinical decision support?
Jehee: We start with depth and whole-genome resolution, then translate that depth into decisions clinicians can use. CancerVision is designed to give oncologists a comprehensive molecular picture by detecting all major mutation types across the genome, so treatment strategy and drug selection aren’t constrained by the limits of narrower panels. MRDVision extends that capability into longitudinal disease monitoring with ultra-sensitive detection, supporting post-treatment management. Across disease stages, our priority is the same: whole-genome insights that are actionable, standardized, and usable in clinical settings.
Saurabh: AI and bioinformatics drive modern genomics. What differentiates Inocras’ proprietary capabilities in translating raw genome data into meaningful insights?
Jehee: We’re bioinformatics-led by design. Our products are sophisticated algorithms built to interpret whole-genome data at scale, and we iterate quickly. What differentiates us is that these algorithms have been refined on thousands of real patient cases, where clinical relevance is earned. Looking ahead, we’re focused on transforming curated WGS datasets into Cancer Genome Intelligence through advanced AI, because cancer is fundamentally a disease of the genome, and whole-genome data gives AI the breadth it needs to learn what smaller datasets can’t.
Saurabh: Integrating whole-genome diagnostics into hospital systems can be complex. What key barriers has Inocras encountered in clinical adoption?
Jehee: The biggest barriers are those that have historically limited WGS in scope: perceived complexity, cost, and skepticism that whole-genome analysis can be standardized for routine use. Our work has been about removing those obstacles, turning WGS into validated, clinically usable solutions that fit physician workflows and provide clear clinical value. The most meaningful signal for us is adoption: once clinicians see the utility in practice, the conversation shifts from “Is WGS ready?” to “How quickly can we implement it?”
Saurabh: Beyond testing, Inocras integrates genetic counseling and trial matching. How do these services enhance precision oncology outcomes?
Jehee: Testing is only valuable if it leads to action. Genetic counseling helps patients and families understand results in a clinically responsible way, and trial matching helps translate genomic findings into options, especially when standard therapies are limited. These services strengthen the bridge between whole-genome insight and real-world care decisions, supporting more informed next steps for clinicians and patients.
Saurabh: Global expansion requires alignment with diverse healthcare systems. What strategic principles guide Inocras’ international growth?
Jehee: Our principle is to scale in the right order: prove clinical value through real-world adoption, build the evidence base clinicians trust, and expand where the ecosystem, partners, infrastructure, and reimbursement can support sustained clinical use. We built strong adoption in Asia, moved our headquarters to San Diego to operate at the center of the global genomics ecosystem, and we’re aligning our next phase, U.S. clinical expansion, with the reimbursement and evidence milestones that can accelerate routine adoption of WGS in care.
Saurabh: Partnerships play a central role in scaling precision medicine. How do collaborations strengthen Inocras’ market positioning?
Jehee: Collaborations strengthen us in two ways: clinical reach and technical leverage. We’ve prioritized partnerships with leading hospitals and research centers to ensure our innovations translate effectively into routine patient care, while working with technology partners to advance performance in areas like ultra-sensitive MRD detection. Partnerships help scale credibility, expand access, and accelerate the adoption of whole-genome insights in everyday care.
Saurabh: With expanding genomic datasets, could Inocras influence future drug development and clinical trial design strategies?
Jehee: Yes, because comprehensive whole-genome datasets can reveal biological patterns and clinically meaningful signals that narrower approaches can miss. Our direction is to transform curated WGS data into Cancer Genome Intelligence using advanced AI, thereby laying the foundation for smarter biomarker strategies and more precise cohort identification over time. We’ve also built strong relationships with biopharma partners globally, which position us to contribute to the development and optimization of trials and therapies as evidence accumulates.
Saurabh: Data governance remains critical in genomics. How does Inocras ensure privacy, compliance, and cross-border regulatory alignment?
Jehee: We operate within regulated clinical frameworks; our testing is validated under CAP and CLIA, and we treat data governance as foundational, not optional. Our public policies describe administrative and technical measures to protect personal information, as well as mechanisms to address individual rights, where applicable. As we expand internationally, our approach is to align with the legal and clinical expectations of each market while maintaining the trust required to responsibly use whole-genome data in care.
Saurabh: Looking ahead, what milestones could make whole-genome sequencing a routine component of standard clinical care?
Jehee: There are three milestones that matter most: (1) standardized clinical validation, (2) clear evidence of superior clinical utility, and (3) reimbursement that supports routine use. We’ve already demonstrated validation and real-world adoption; our WGS-based tests are used by more than 200 oncologists, primarily in Asia, as part of daily practice. The next accelerant is broader clinical evidence and reimbursement momentum, particularly in the U.S., which can help move oncology beyond limited panels and into whole-genome-driven standard care.
Saurabh: Inocras has previously announced work with the Broad Institute of MIT and Harvard. What is the focus of that collaboration, and what do you hope it enables?
Jehee: We entered an agreement with researchers at the Broad Institute of MIT and Harvard to jointly analyze whole-genome sequencing data from big sets of tumor/normal paired samples, with the goal of advancing what we can learn from whole cancer genomes and accelerating progress in precision oncology. As publicly described, the project sponsors multiple Broad research teams to analyze a substantial cancer whole-genome dataset. Our intent is to combine Broad’s scientific leadership with Inocras’ whole-genome analytics capabilities to deepen genome-wide understanding that can ultimately translate into better diagnostic and treatment strategies.
About Jehee Suh
Jehee Suh, the Chief Executive Officer of Inocras, brings more than 20 years of experience as a business leader in the life sciences industry. His strategic vision has been instrumental in leading the company’s rapid growth.
Prior to his current position, Jehee held CEO and senior executive roles at various biotech companies, where he managed both early-stage and clinical assets. He also worked as a brand manager at Novartis and served as a Partner at McKinsey & Company, advising top-tier life sciences leaders. He earned an MBA from the Wharton School.
Related Post: Whole-genome sequencing meets real-world outcomes: what 1,364 breast cancer genomes reveal about treatment response
